AGS67E
Phase 1Completed 1 views this week 0 watching💤 Quiet
Interest: 29/100
29
Development Stage
✓
Pre-clinical2
Phase 13
Phase 24
Phase 35
ApprovedIndication / Disease
Relapsed Lymphoid Malignancy
Conditions
Relapsed Lymphoid Malignancy, Refractory Lymphoid Malignancy
Trial Timeline
Oct 14, 2014 → Oct 29, 2019
NCT ID
NCT02175433About AGS67E
AGS67E is a phase 1 stage product being developed by Astellas Pharma for Relapsed Lymphoid Malignancy. The current trial status is completed. This product is registered under clinical trial identifier NCT02175433. Target conditions include Relapsed Lymphoid Malignancy, Refractory Lymphoid Malignancy.
What happened to similar drugs?
2 of 20 similar drugs in Relapsed Lymphoid Malignancy were approved
Approved (2) Terminated (2) Active (16)
🔄SHR2554; Chidamide analog tablets + SHR2554 analog tablets; ChidamideJiangsu Hengrui MedicinePhase 3
Hype Score Breakdown
Clinical
6
Activity
8
Company
15
Novelty
0
Community
0
Clinical Trials (2)
| NCT ID | Phase | Status |
|---|---|---|
| NCT02610062 | Phase 1 | Terminated |
| NCT02175433 | Phase 1 | Completed |
Competing Products
20 competing products in Relapsed Lymphoid Malignancy